The efficacy of tyrosine kinase inhibitor dasatinib on colonic mucosal damage in murine model of colitis

Basit Öğe Kaydı
dc.contributor.authorCan, Güray
dc.contributor.authorAyvaz, Süleyman
dc.contributor.authorCan, Hatice
dc.contributor.authorKaraboğa, İhsan
dc.contributor.authorDemirtaş, Selim
dc.contributor.authorAkşit, Hasan
dc.contributor.authorYılmaz, Bülent
dc.date.accessioned2020-03-26T19:31:41Z
dc.date.available2020-03-26T19:31:41Z
dc.date.issued2016
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground and objective: Ulcerative colitis is an inflammatory condition of the colon in the gastrointestinal system. Currently, the most potent medications used for ulcerative colitis produce no response in 20-30% of cases. There is a need for more efficient and reliable medications. Tyrosine kinase inhibitors have shown efficacy in some inflammatory diseases. Although dasatinib, a tyrosine kinase inhibitor, suppresses proinflammatory cytokines in colonic tissue, there are a few cases of hemorrhagic colitis with dasatinib. There is no study investigating the effect of dasatinib on experimental colitis. We aimed to investigate the effect of dasatinib in a colitis model induced with acetic acid in our study. Methods: In the study, 24 male Sprague-Dawley rats randomly distributed into 4 groups of 6 rats each as control, dasatinib, colitis and dasatinib + colitis groups. For colitis induction, 4% acetic acid was used. Sacrificing of the rats was performed on the seventh day. Disease activity, morphologic and histological injury, superoxide dismutase, myeloperoxidase and malondialdehyde activity, TNF alpha and CD3 expression were assessed in colonic tissue. Results: Apart from malondialdehyde, significant difference in all parameters between the control and colitis groups was determined. Difference between the colitis and colitis + dasatinib groups was not significant in only weight loss and biochemical parameters. Though dasatinib does not fully resolve the changes in colitis, there was significant regression. Conclusions: Dasatinib decreased the inflammation in a rodent model of colitis. It may be provide this effect by the suppression of TNF alpha. Dasatinib may be one of the treatment options for ulcerative colitis. (C) 2016 Elsevier Masson SAS. All rights reserved.en_US
dc.identifier.doi10.1016/j.clinre.2015.12.006en_US
dc.identifier.endpage516en_US
dc.identifier.issn2210-7401en_US
dc.identifier.issn2210-741Xen_US
dc.identifier.issue4en_US
dc.identifier.pmid26823039en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage504en_US
dc.identifier.urihttps://dx.doi.org/10.1016/j.clinre.2015.12.006
dc.identifier.urihttps://hdl.handle.net/20.500.12395/34091
dc.identifier.volume40en_US
dc.identifier.wosWOS:000388875200024en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherELSEVIER MASSON, CORPORATION OFFICEen_US
dc.relation.ispartofCLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.titleThe efficacy of tyrosine kinase inhibitor dasatinib on colonic mucosal damage in murine model of colitisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu